PriceTargets.com logo

OTCMKTS:THERF - Theratechnologies Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.20 As of 08/11/2022 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for THERF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Theratechnologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for THERF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for THERF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Theratechnologies in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.20.

This chart shows the closing price for THERF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Theratechnologies. This rating has held steady since September 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/18/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/19/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/17/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/13/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/14/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/13/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/12/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/9/2019Royal Bank of CanadaSet Price TargetHold$6.00
10/9/2019MackieReiterated RatingHold
9/4/2018Royal Bank of CanadaInitiated CoverageSector Perform
(Data available from 8/12/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/14/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/13/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/15/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/14/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/14/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/13/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/13/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/12/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Theratechnologies logo
Theratechnologies Inc., a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada and the United States; and Trogarz, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients in the United States. The company was founded in 1993 and is headquartered in Montreal, Canada.
Read More

Today's Range

Now: $2.20
Low: $2.17
High: $2.25

50 Day Range

MA: $2.28
Low: $2.02
High: $2.69

52 Week Range

Now: $2.20
Low: $3.58
High: $7.29

Volume

11,234 shs

Average Volume

45,196 shs

Market Capitalization

$169.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Theratechnologies?

The following Wall Street sell-side analysts have issued reports on Theratechnologies in the last twelve months:
View the latest analyst ratings for THERF.

What is the current price target for Theratechnologies?

0 Wall Street analysts have set twelve-month price targets for Theratechnologies in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Theratechnologies in the next year.
View the latest price targets for THERF.

What is the current consensus analyst rating for Theratechnologies?

Theratechnologies currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for THERF.

What other companies compete with Theratechnologies?

Other companies that are similar to Theratechnologies include Artelo Biosciences, Vaccitech, Olema Pharmaceuticals, ProPhase Labs and Trevi Therapeutics. Learn More about companies similar to Theratechnologies.

How do I contact Theratechnologies' investor relations team?

Theratechnologies' physical mailing address is 2015 Peel Street 5th Floor, MONTREAL A8, H3A 1T8. The company's listed phone number is 514-336-7800 and its investor relations email address is [email protected] The official website for Theratechnologies is www.theratech.com. Learn More about contacing Theratechnologies investor relations.